66 drugs, business commitment: not available nationwide (listed)

Pharmaceutical network on May 25th, 66 drugs, enterprise commitment: the country does not supplyOn May 21, Shanxi Province's centralized bidding procurement network issued two notices to withdraw the network, involving a total of 66 product regulationsFrom the above notice we can find that these 66 product regulations are actively removed from the net, including double yellow even particles, clear-cut injections and other traditional Chinese medicine, but also includes the hydrochloric acid Benapri tablets, tubmycin eye drops, claricin capsules and other commonly used drugsIn addition to the withdrawal of the internet in Shanxi, these, the relevant pharmaceutical companies have provided a "national unified non-supply commitment."that is, the 66 drugs are not sold incountryAccording to the notice, 66 drugs are not available nationwide, mainly due to the increase in raw material prices, production line transformation, environmental pollution and other reasons, resulting in the discontinuation of drugsThe reasons for these big shutdowns, for theindustry, can not be more familiarsaid that the price of raw materials, we should be deeply touchedIn recent years, the price of some API prices, can be described as alarmingFor example, in 2019, the State Administration of Market Supervision received reports that pharmaceutical distribution companies monopolized the injection of calcium gluconate api, resulting in a shortage of calcium gluconate injections, prices rose sharplySales of injectable calcium glucose acid apis rose 19 times to 54.6 times in 2017 compared to 2014 pricesearlier, Malay acid chlorobenzene in a month, from 400 yuan / kg to 23,300 yuan / kg, a 58-fold increase, phenol is from 230 yuan / kg to 23,000 yuan / kg, up to 99 timesbut in the case of Chinese medicine, the price of Chinese has soared in recent years Insiders say that in recent years, as raw materials for traditional Chinese medicine, some prices have turned a few fights soars the cost of pharmaceutical companies, as well as investment in environmental protection Since the introduction of the environmental tax, emissions of atmospheric and water pollutants the most affected Industry analysis, the current domestic pharmaceutical enterprises have a certain scale, if calculated in accordance with environmental tax laws, only sewage treatment costs will be hundreds of millions of yuan, and not including exhaust gas, solid waste and so on at such a high cost, the price of drugs, but the pressure Relevant pharmaceutical companies said that because some products are too low bid price, after winning the bid has not been produced there is also a situation where there is too much competition and there is not much sales Pharmaceutical companies see fierce competition, sales are very small, so some companies decided to stop production, it is also reasonable attached: Shanxi Province to revoke the registration of the internet qualification drug product regulations published implementation directory 20200521